Ionis Pharmaceuticals (IONS) PT Raised to $59 at TD Cowen

TD Cowen analyst Yaron Werber raised the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $59.00 (from $54.00) while maintaining a Buy rating.

The analyst commented, "In conjunction with our Q2 Earnings Preview, we are updating our model to reflect assumptions about likely Q2 and future drug sales as well as interest/other expense assumptions based on our conversations with management."

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• RBC Capital on Veeva Systems (VEEV) Amid After Hours Selloff on Earnings: 'we are surprised to see shares trade down'
• Goldman Sachs Upgrades Plains All American (PAA) to Neutral